Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Guelph

$24,000.00

The effects of BCG-lytic peptide conjugates on ovarian function in ewes

FY 2009-10

Summary
Reproductive tissue cancers are of primary concern for biomedical research, with prostate and breast cancers being the most frequent forms seen in men and women, respectively. Ovarian cancers continue to be a leading gynaecological cause of death in North American women. As conventional cancer therapy has proven less than ideal, the search for a more selective type of treatment has lead to the development of conjugated lytic peptides. The conjugated lytic peptides consist of small, cell-disrupting peptides linked to the fragments of gonadotropin hormones, allowing them to target cancer tissue specifically expressing the lutropin/choriogonadotropin (LH/CG) receptor. A distinct advantage of targeting breast, prostate and ovarian cancers with the lytic peptide conjugated to the fragment of CG molecule is that reproductive tissues and reproductive tissue cancers express the LH/CG receptor in much greater abundance than other tissues throughout the body. In mice, conjugated lytic peptides have been able to effectively destroy cancer cells and reduce the tumour burden while reportedly causing little damage to healthy organs. However, there is a lack of information on their effects on normal ovarian structures during different stages of the ovulatory cycle. Thus, the aim of the proposed studies is to determine the effects of one such conjugate, Phor21-ßCG(ala) and its enantiomer ßCG(ala)-Phor21, on the ovarian processes governed by endogenous LH. As an initial approach, ultrasound images and reproductive hormone measurements will be used for real-time assessment of antral follicular development, ovulation and luteal structures, using sheep as an experimental model. It is predicted that the dense expression of LH receptors on the preovulatory follicle and corpus luteum (CL) will present an appropriate target the conjugates, and disrupt normal ovarian function. As these drugs move towards human clinical trials, it is of great importance to have evidence indicating their effects on the dynamic processes in the ovaries, in a large mammalian animal model. This may have important bearing on the use of Phor21-ßCG(ala) and ßCG(ala)-Phor21 as therapeutic agents, or potentially in a contraceptive role or as a research tool in the future.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
311647-2009
Name nom
Bartlewski, Pawel
Department département
Biomedical Sciences
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
24000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1011
Committee name en
Integrative Animal Biology
Committee name fr
Biologie Animale Intégrative
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5505
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal reproduction
Research subject fr
Reproduction animale
Partie
1
Nb partie
1
Application title
The effects of BCG-lytic peptide conjugates on ovarian function in ewes
Keyword
NA
Application summary
Reproductive tissue cancers are of primary concern for biomedical research, with prostate and breast cancers being the most frequent forms seen in men and women, respectively. Ovarian cancers continue to be a leading gynaecological cause of death in North American women. As conventional cancer therapy has proven less than ideal, the search for a more selective type of treatment has lead to the development of conjugated lytic peptides. The conjugated lytic peptides consist of small, cell-disrupting peptides linked to the fragments of gonadotropin hormones, allowing them to target cancer tissue specifically expressing the lutropin/choriogonadotropin (LH/CG) receptor. A distinct advantage of targeting breast, prostate and ovarian cancers with the lytic peptide conjugated to the fragment of CG molecule is that reproductive tissues and reproductive tissue cancers express the LH/CG receptor in much greater abundance than other tissues throughout the body. In mice, conjugated lytic peptides have been able to effectively destroy cancer cells and reduce the tumour burden while reportedly causing little damage to healthy organs. However, there is a lack of information on their effects on normal ovarian structures during different stages of the ovulatory cycle. Thus, the aim of the proposed studies is to determine the effects of one such conjugate, Phor21-ßCG(ala) and its enantiomer ßCG(ala)-Phor21, on the ovarian processes governed by endogenous LH. As an initial approach, ultrasound images and reproductive hormone measurements will be used for real-time assessment of antral follicular development, ovulation and luteal structures, using sheep as an experimental model. It is predicted that the dense expression of LH receptors on the preovulatory follicle and corpus luteum (CL) will present an appropriate target the conjugates, and disrupt normal ovarian function. As these drugs move towards human clinical trials, it is of great importance to have evidence indicating their effects on the dynamic processes in the ovaries, in a large mammalian animal model. This may have important bearing on the use of Phor21-ßCG(ala) and ßCG(ala)-Phor21 as therapeutic agents, or potentially in a contraceptive role or as a research tool in the future.